(Q50966629)

26 March 2018

title

Production of interferon-gamma in families with multiple occurrence of schizophrenia. (English)

1 reference

26 March 2018

0 references

Arolt V

1

1 reference

26 March 2018

Weitzsch C

2

1 reference

26 March 2018

Wilke I

3

1 reference

26 March 2018

Nolte A

4

1 reference

26 March 2018

Pinnow M

5

1 reference

26 March 2018

Rothermundt M

6

1 reference

26 March 2018

Kirchner H

7

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 February 1997

1 reference

26 March 2018

published in

Psychiatry Research

1 reference

26 March 2018

volume

66

1 reference

26 March 2018

issue

2-3

1 reference

26 March 2018

page(s)

145-152

1 reference

26 March 2018

Eye tracking dysfunction in families with multiple cases of schizophrenia.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Serum Interferon in First Psychotic Attack

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Decreased interleukin-2 production in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

The genetics of schizophrenia: a current, genetic-epidemiologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

A whole-blood technique for testing production of human interferon by leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Eye tracking dysfunction and schizophrenia: a critical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Serum interferon in patients with psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Elevated levels of soluble interleukin 2 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Changes of immunological functions after acute exacerbation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Decreased production of interleukin-2 in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2896%2903023-5

7 January 2021

10.1016/S0165-1781(96)03023-5

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018